Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors

17 Jul 2008

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 18674509
DOI: 10.1016/j.ab.2008.07.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitorsPMID 18674509Read ↗

Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in OncologySemantic proximity Read ↗

Poly(ADP-Ribose) Polymerase InhibitorsSemantic proximity Read ↗

PARP inhibitors: New partners in the therapy of cancer and inflammatory diseasesSemantic proximity Read ↗

The clinical development of inhibitors of poly(ADP-ribose) polymeraseSemantic proximity Read ↗

Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary TargetsSemantic proximity Read ↗

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic BiomarkersSemantic proximity Read ↗

PARP inhibitors coming of ageSemantic proximity Read ↗

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.Semantic proximity Read ↗

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancerSemantic proximity Read ↗

Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?Semantic proximity Read ↗

Delving into PARP inhibition from bench to bedside and backSemantic proximity Read ↗

PARP1 expression, activity andex vivosensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.